Division of Transfusion Medicine, Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Transfusion. 2022 Nov;62(11):2271-2281. doi: 10.1111/trf.17116. Epub 2022 Sep 20.
Due to the coronavirus disease 2019 (COVID-19) pandemic, the transfusion medicine community has experienced unprecedented blood supply shortages since March 2020. As such, numerous changes to everyday practice have occurred with a specific emphasis on blood conservation. We sought to determine the strategies used to mitigate blood shortages and promote blood conservation during the pandemic.
An anonymous, 37-question survey was developed using Research Electronic Data Capture and distributed via e-mail to transfusion medicine specialists across the US obtained via publicly available databases.
Amongst surveyed [41.1% response rate (51/124 institutions)], 98.0% experienced a product shortage, with the greatest number reporting red blood cell (RBC) shortages (92.0%). This led to 35.3% of institutions altering the composition and/or number of blood product suppliers, including a 100% increase in the number of institutions acquiring blood from organizations that connect hospital transfusion services with blood collection centers (e.g., Blood Buy) compared to before March 2020. Prospective triaging of blood products was the most common blood conservation strategy (68.1%), though 35.4% altered their RBC exchange or transfusion program for patients receiving chronic RBC transfusion/exchange. As a result of these changes, 78.6% of institutions reported that these changes resulted in a reduction in blood product usage, and 38.1% reported a decrease in product wastage.
Most hospitals experienced the effects of the supply shortage, and many of them implemented blood conserving measures. Conservation strategies were associated with decreased blood utilization and waste, and future studies could evaluate whether these changes persist.
由于 2019 年冠状病毒病(COVID-19)大流行,自 2020 年 3 月以来,输血医学领域经历了前所未有的血液供应短缺。因此,日常实践发生了许多变化,特别强调了血液保存。我们旨在确定在大流行期间减轻血液短缺和促进血液保存的策略。
使用 Research Electronic Data Capture 开发了一项匿名的,包含 37 个问题的调查,并通过电子邮件分发给美国各地的输血医学专家,这些专家是通过公开可用的数据库获得的。
在所调查的[41.1%的应答率(51/124 个机构)]中,98.0%的机构经历了产品短缺,其中报告红细胞(RBC)短缺的机构数量最多(92.0%)。这导致 35.3%的机构改变了血液制品供应商的组成和/或数量,与 2020 年 3 月之前相比,包括通过将医院输血服务与采血中心联系起来的组织(例如 Blood Buy)获得血液的机构数量增加了 100%。血液制品的前瞻性分类是最常见的血液保存策略(68.1%),尽管 35.4%的机构改变了接受慢性 RBC 输血/交换的患者的 RBC 交换或输血计划。由于这些变化,78.6%的机构报告说这些变化导致血液制品的使用减少,38.1%的机构报告产品浪费减少。
大多数医院都受到供应短缺的影响,其中许多医院实施了血液保存措施。保存策略与血液利用率和浪费的减少有关,未来的研究可以评估这些变化是否持续。